Pharmacological cardioversion of nifekalant for ventricular fibliration or tachycardia following reperfuion

Pharmacological cardioversion of nifekalant for ventricular fibliration or tachycardia following reperfuion - Pharmacological cardioversion of nifekalant

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032758

Enrollment

Registered

2018-08-28

Start date

2018-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing cardiac surgery with cardiopulmonary bypass

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Occurrance of ventricular fiblilation or tachycardia following aortic declamping

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
successdul cardioversion or not	—

Countries

Japan

Contacts

Public ContactYukio Hayashi

Sakurabashi- Watanabe Hospital Anesthesiology

yhayashi@anes.med.osaka-u.ac.jp06-6341-8651

Outcome results